Printer Friendly

BIOCUREX/GOSHEN CANCER CENTER DEVELOPING RECAF.

BioCurex Inc., Richmond, British Columba, has initiated a collaboration with the Center for Cancer Care in Goshen, Indiana, for developing and evaluating its RECAF(tm) technology.

The collaboration with Biocurex and the Center for Cancer Care is long term and will consist of three phases: The first one will continue and expand the applications of serum and biopsy tests using RECAF(tm). The second phase will focus on imaging applications using RECAF(tm) to detect the location of cancerous tumors in the body. The third phase includes clinical trials in which RECAF(tm) will be used as a way to specifically deliver therapeutic agents to destroy the cancer cells with minimal damage to normal tissues. The third phase is contingent to the previous development of animal and culture models demonstrating the benefits of RECAF for targeting cancer cells.

Dr. Douglas Schwartzentruber, medical director of Goshen Health System's Center for Cancer Care stated, "In many ways this is an ideal partnership that brings together the strengths of our institutions, both in the basic sciences and the clinical arena."

Dr. Douglas Schwartzentruber is a surgical oncologist who completed a fellowship in Immunotherapy at the National Cancer Institute, Bethesda, Maryland where he subsequently worked for 13 years as a senior investigator. Dr. Schwartzentruber's research on the role of vaccines in the treatment of malignant melanoma, has gained both national and international attention. He serves on the editorial board for the American Journal of Oncology Review and the Journal of Translational Medicine.

Dr. Moro, CEO of BioCurex stated, "This collaboration represents a significant strategic move for us. Once we finalize the process of licensing the diagnostic applications of the RECAF technology, we shall move the focus of the company to its next logical level, which includes cancer imaging and therapy. We have already started research efforts in this direction and the initial results are encouraging."

Moro continued, "We are very happy with the collaboration with Goshen Health System's Center for Cancer Care because their knowledge will provide our group with a comprehensive understanding of the needs in the clinical cancer arena. Moreover, their access to patients, their ability to develop clinical trials and most importantly, their unusual interest and commitment to research is foretelling of a very successful collaboration."

A cancer marker allows one to distinguish cancer cells from non-cancerous cells. RECAF(tm) is a cancer marker exclusively developed and patented by BioCurex, Inc. Cancer markers most widely used in the detection and treatment of cancer include AFP, CEA, PSA and Ca125. An ideal cancer marker is a molecule present in all cancer cells but not in normal or benign tumor cells. RECAF(tm) could become the one cancer marker suitable to detect all cancer types. The potential benefit RECAF(tm) offers to patients is a superior diagnostic tool and a new way to deliver targeted therapy.

The Center for Cancer Care of Goshen Health System (CCC/GHS), a leader in innovative cancer treatment, is among Indiana's first cancer centers to adopt a comprehensive approach to treatment. CCC/GHS offers holistic programs for strengthening minds as well as bodies, placing a premium on family involvement and spiritual needs. CCC/GHS encourages patients to play a decision-making role in treatment selection.

CCC/GHS provides comprehensive cancer care in a state-of-the-art facility on the campus of Goshen General Hospital. The Center participates in programs with the National Surgical Adjuvant Breast and Bowel Project (NSABP), Eastern Cooperative Oncology Group (ECOG), Hoosier Oncology Group (HOG), The NCI's Clinical Trials Support Unit (CTSU) and Michigan State University (MSU). The Center is currently involved in over 40 clinical trials.

For more information, visit http://www.cancermidwest.com.

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

For more information, visit http://www.biocurex.com or call 604/207-9150.
COPYRIGHT 2005 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Jul 1, 2005
Words:676
Previous Article:NEWLY-ENGINEERED SYNTHETIC AFGP STABLE/NON-TOXIC.
Next Article:SFDA GRANTS MIRACLE LASER APPROVAL TO SELL SYNERON PRODUCTS.


Related Articles
Bukiet homes built in Goshen.
Vandals for gay marriage.
Full-service subversion.
UNCONTROLLED BURN.
RECAF BLOOD TEST DETECTS 92% OF CERVICAL CANCERS.
BRIEFLY.
BRIEFLY.
Ganter, Amy Kim. Sorcerers and Secretaries.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters